Core Insights - VolitionRx Limited has made significant clinical and commercial progress, highlighting licensing momentum and advancements in various diagnostic technologies [1][2] Group 1: Licensing and Commercialization - The company is in active discussions with approximately 10 global diagnostic leaders for licensing agreements [1][2] - Anticipated announcements of additional agreements during 2026 as negotiations progress [2] Group 2: Clinical Developments - The Nu.Q® NETs assay is included in a $7.3 million government-backed DETECSEPS program in France for early sepsis detection [1] - A reimbursement submission for lung cancer testing in France is underway, with routine clinical use expected by Q4 2026 [1] - New clinical utility of the Nu.Q® NETs assay has been demonstrated for managing Hidradenitis Suppurativa, a disease affecting about 1% of the global population [1] Group 3: Market Opportunities - The Capture-Seq™ platform presents a $23 billion annualized opportunity in cancer detection [1][2] - The total addressable market for Nu.Q® NETs in sepsis and chronic conditions is estimated at $3.8 billion [2] - The Nu.Q® Vet (Canine/Feline) market is projected to exceed $1 billion, with the canine test already commercially available [2] Group 4: Veterinary Breakthroughs - The Nu.Q® Vet Feline assay achieved 100% specificity in detecting feline lymphoma, marking a significant advancement in veterinary diagnostics [1] - This breakthrough is expected to unlock a $5 million milestone payment upon publication in a peer-reviewed journal [1]

Core Insights - VolitionRx Limited has appointed Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor for its Nu.Q® Discover assays in Japan, enhancing its market presence in the region [1] - The company serves nearly 100 clients globally, including major pharmaceutical and diagnostic firms, and anticipates continued revenue growth for Nu.Q® Discover in 2026 [1] - The Total Accessible Market for relevant companion diagnostics is estimated to be just under $1 billion, indicating significant growth potential [1] Company Developments - The collaboration with MBL is expected to generate interest and data for potential future regulatory applications for diagnostic status in Japan [1] - In 2025, Volition achieved several milestones, including a co-marketing agreement with Hologic Diagenode and the first commercial sale of its High Throughput Synthetic Sepsis method [1] - The Nu.Q® Discover program provides advanced assays for rapid epigenetic profiling, supporting drug developers and researchers in various therapeutic areas [1] Market Context - MBL, established in 1969, is a leading provider of clinical research tools in Japan, focusing on autoimmune diseases and genetic diagnostics [1] - The partnership aims to expand access to nucleosome-based biomarkers for drug developers and researchers, contributing to advancements in personalized medicine [1] - VolitionRx is dedicated to improving disease detection and monitoring through cost-effective blood tests, with a focus on cancers and diseases related to NETosis [1]

Core Viewpoint - VolitionRx Limited has received a notice of non-compliance from NYSE American regarding its continued listing standards due to insufficient stockholders' equity, requiring a plan to regain compliance by August 6, 2027 [1][2] Compliance Requirements - The company is not in compliance with Section 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide, which mandates stockholders' equity of at least $2.0 million, $4.0 million, and $6.0 million respectively, based on reported losses over recent fiscal years [1] - Volition must submit a compliance plan by March 8, 2026, detailing actions to regain compliance [1] Delisting Proceedings - If the plan is not submitted or accepted, or if compliance is not achieved by the deadline, NYSE American will initiate delisting proceedings [1] - The common stock will continue to trade under the symbol "VNRX" with an added designation of ".BC" indicating "below compliance" status [1] Business Operations - The notice does not impact the ongoing business operations or reporting requirements of the company with the U.S. Securities and Exchange Commission [1] - Volition is committed to regaining compliance and plans to submit a detailed plan to the NYSE American [1]

Core Viewpoint - VolitionRx Limited is sponsoring a symposium at the European Hidradenitis Suppurativa Foundation Conference to present findings on the Nu.Q NETs assay, which aids in the management of Hidradenitis Suppurativa (HS) through a precision medicine approach [1][2][3]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for patients through earlier detection and monitoring of diseases [11][12]. - The company is developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, aiming to enhance patient quality of life [12]. Industry Context - Hidradenitis Suppurativa (HS) is a chronic condition affecting approximately 1% of the global population, characterized by painful skin abscesses and scarring [3][9]. - The condition is difficult to manage, and the introduction of biological treatments has shown varied responses among patients, highlighting the need for a precision medicine approach [4][9]. Product and Market Potential - The Nu.Q NETs assay is CE-Marked for clinical use in 27 EU member states and is positioned as a simple, low-cost test to detect diseases associated with NETosis, with a total addressable market estimated at $3.8 billion [6][8]. - The assay aims to classify HS patients and guide treatment decisions, potentially improving patient management and outcomes [4][6].

Core Insights - VolitionRx Limited is preparing a reimbursement submission for its Nu.Q® Cancer assays in France, supported by the Hospices Civils de Lyon, aiming for clinical certification of the test [1][2][3] Group 1: Company Developments - The reimbursement submission is expected to be completed by the end of the current quarter under the "Innovative Procedures Outside the Nomenclature" framework, with a determination of eligibility for reimbursement coverage anticipated within five months [2][3] - VolitionRx aims to introduce the Nu.Q® test into routine clinical use in France by the fourth quarter of 2026, marking a significant milestone in the commercialization of its cancer diagnostics [3] Group 2: Clinical and Market Impact - There are approximately 50,000 new lung cancer diagnoses annually in France, with a five-year prevalence of around 65,000 cases, indicating a substantial market opportunity for the Nu.Q® Cancer assays [3] - The Nu.Q® test is expected to enhance precision in treatment selection and monitoring for lung cancer patients, providing valuable information regarding survival and progression-free survival [2][3] Group 3: Collaborations and Support - The collaboration with Hospices Civils de Lyon is crucial for the submission process, as they are France's second-largest university hospital system, which will facilitate the integration of the Nu.Q® test into clinical practice [2][5] - The support from HCL underscores the strong scientific and clinical evidence developed over several years to validate the use of Nu.Q® in cancer management [2]

Core Insights - VolitionRx Limited has appointed two new centralized laboratory providers for its Nu.Q® Vet Cancer test, enhancing access to its canine cancer early detection tool in the U.S. and Asia [1][7] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics to improve outcomes for people and animals through earlier detection of diseases [3][4] - The company is dedicated to developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, such as sepsis [4] Market Opportunity - The Total Addressable Market (TAM) for the Nu.Q® Vet Cancer test is approximately $100 million across the U.S., Europe, and Japan, which could increase to nearly $150 million with the inclusion of China [3][7] Product Development - The Nu.Q® Canine Cancer Test can be integrated into annual checkups or senior wellness exams, allowing veterinarians to detect cancer earlier and assist pet owners in making informed decisions regarding cancer care [2][4]

Core Insights - VolitionRx Limited is sponsoring an industry symposium at the Veterinary Meeting and Expo (VMX) in Orlando, Florida, where Dr. Sue Ettinger will present on the Nu.Q® Vet Cancer Test [1][2] Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve outcomes for people and animals with life-altering diseases through earlier detection and monitoring [4] - The company is developing cost-effective blood tests for detecting and monitoring various diseases, including cancers and conditions associated with NETosis, such as sepsis [5] Industry Engagement - VMX 2026 is expected to attract approximately 20,000 veterinary professionals, providing a significant platform for Volition to showcase its Nu.Q® Test [3] - The Volition Veterinary Diagnostics Development team will be present at booth 2243 during the conference [3]

Core Viewpoint - VolitionRx Limited has entered into an amended agreement with Lind Global Asset Management to secure $2,000,000 in funding through the issuance of a senior secured convertible promissory note and a common stock purchase warrant, enhancing its financial position for future growth [1][2]. Group 1: Financial Details - The company will issue a senior secured convertible promissory note with a principal amount of $2,400,000 and a common stock purchase warrant to purchase up to 7,000,350 shares at an exercise price of $0.5714 per share [1]. - The 2026 Note will be repaid in eighteen monthly installments of $133,333 starting six months after issuance, with the option for the investor to increase payments up to $1,000,000 for two months [3]. - A commitment fee of $70,000 will be paid to the investor, deducted from the funding received [1]. Group 2: Previous Agreements - The amended agreement updates a previous securities purchase agreement from May 15, 2025, where the company issued a senior secured convertible promissory note of $7,500,000 and a warrant for 13,020,834 shares [2]. - Both the 2025 and 2026 Notes are secured by the assets of the company and its subsidiaries [2]. Group 3: Regulatory Compliance - The company is required to file a registration statement within 30 days of closing to cover the resale of shares issued upon conversion of the 2026 Note or exercise of the 2026 Warrant [4]. Group 4: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve early detection and monitoring of diseases, including cancers and conditions associated with NETosis [6][7]. - The company's research and development activities are primarily based in Belgium, with additional offices in the U.S. and London [8].

Core Insights - VolitionRx Limited has developed the Nu.Q® Vet Feline assay, achieving 100% specificity and detecting over 80% of feline lymphomas, marking a significant advancement in veterinary cancer diagnostics [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on early detection of diseases, including cancers, through blood tests [6][7] - The company aims to make cancer screening a routine part of annual wellness checks for pets, having already successfully rolled out a canine cancer test [3][6] Market Opportunity - The introduction of the feline cancer test could potentially double Volition's total addressable market in the companion animal space, as the canine test is already available in over 20 countries [4][5] - There are approximately 73.8 million pet cats in the U.S., with an estimated 1 in 5 cats likely to develop cancer in their lifetime, highlighting a significant market need [5] - The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with the feline segment expected to grow at a faster rate than the canine segment due to increasing owner awareness [5] Product Development and Revenue Potential - The successful publication of the study in a peer-reviewed journal is anticipated to unlock a $5 million contractual milestone payment for Volition [5] - The company is focused on completing product development and making the Nu.Q® Vet Feline Test available through existing distribution networks [3][4]

Company Overview - VolitionRx is focused on saving lives and improving outcomes through low-cost testing in cancer, sepsis, and veterinary applications[4, 5] - The company operates with a low capex, low opex business model, emphasizing commercial partnerships and out-licensing[21] - VolitionRx leverages its IP Powerhouse with 56 patent families and a team with hundreds of years of experience[5] Commercialization and Licensing - The company received $10 million upfront and $13 million in milestone payments from an exclusive Element i+ in-house analyzer licensing partnership[29] - In 2024, Volition sold over 120,000 Nu.Q® Vet Cancer Tests & Components[40] - The company is targeting multiple licensing deals in the human space in 2026, focusing on upfront, milestone, and recurring revenue[25] Products and Market - Nu.Q® Vet is available in the United States, Europe, and Asia, detecting 76% of systemic cancers at 97% specificity[38, 40] - The company estimates a $170 million non-regulated animal testing licensing market, a $4 billion lab-developed screening/management market, and a >$3 billion ICU/ED CE Mark/FDA NETosis sales & licensing market[36] - Lung cancer screening and disease management with Nu.Q® is forecasted to reach over 3 million tests by 2035[63]